- Oops!Something went wrong.Please try again later.
"Much the way Amazon has become the go-to platform for buyers and sellers of consumer goods," the analyst believes iSpecimen can become the go-to platform for human biospecimens, writes analyst Matthew Hewitt.
The analyst notes that though the Company was founded in 2009, it has only recently reached a critical mass of buyers and sellers, with revenue for 2021 on track to be nearly triple the 2019 level.
The Company offers a range of biofluids, tissue, and stem and immune cells, including specimens with genetic variants (such as COVID-19 variants).
Recently, iSpecimen expanded its global supplier network, with 25% of its newest specimen suppliers in 2021 coming from outside the U.S.
Throughout 2021, iSpecimen has added nearly two dozen biospecimen suppliers to its network across the U.S., Europe, and Asia-Pacific.
In December, iSpecimen expanded its global biospecimen provider network to support research related to neurological disorders.
Price Action: ISPC shares are up 7.20 at $8.64 during the market session on the last check Tuesday.
Latest Ratings for ISPC
Initiates Coverage On
See more from Benzinga
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.